Loading...
•
Mar 31, 2022
Avadel Q1 2022 Earnings Report
Announced financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Key Takeaways
Avadel Pharmaceuticals reported a net loss of $26.4 million, or ($0.45) per diluted share, for the quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities were $123.5 million as of March 31, 2022. The company continues to work with the FDA to complete the review of its NDA for FT218.
NDA for FT218 continues in late-stage review.
Belief in the full approvability of FT218 based on interactions with the FDA to date.
Presented important interim results from the ongoing open-label RESTORE study of FT218.
Cash, cash equivalents and marketable securities were $123.5 million as of March 31, 2022.
Forward Guidance
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...